Over the past decade, antimicrobial blue light (aBL) at 400 nm - 470 nm wavelength has demonstrated immense promise as an alternative approach for the treatment of multidrug-resistant microbes. Since our last review was published in 2017, there have been numerous studies that have investigated the efficacy, safety, mechanism, and propensity for resistance development. In addition, researchers have looked at combinatorial approaches that exploit aBL and other traditional and non-traditional therapeutics. To that end, this review aims to update the findings from numerous studies that capitalize on the antimicrobial effects of aBL, with a focus on: efficacy of aBL against different microbes, identifying endogenous chromophores and targets of aBL, Resistance development to aBL, Safety of aBL against host cells, and Synergism of aBL with other antimicrobials. We will also discuss our perspective on the future of aBL.

在过去十年中，400 nm - 470 nm 波长的抗菌蓝光 (aBL) 作为治疗多重耐药微生物的替代方法显示出巨大的前景。自我们上次审查于 2017 年发表以来，已有大量研究调查了耐药性发展的疗效、安全性、机制和倾向。此外，研究人员还研究了利用 aBL 和其他传统和非传统疗法的组合方法。为此，本综述旨在更新大量利用 aBL 抗菌作用的研究结果，重点是：aBL 对不同微生物的功效、鉴定内源性生色团和 aBL 靶标、对 aBL 的耐药性发展、安全性aBL 针对宿主细胞，aBL 与其他抗菌剂的协同作用。我们还将讨论我们对 aBL 未来的看法。